Format

Send to

Choose Destination
J Am Heart Assoc. 2019 Jan 8;8(1):e009122. doi: 10.1161/JAHA.118.009122.

Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study.

Author information

1
1 Department of Pediatric Oncology Emma Children's Hospital Amsterdam UMC University of Amsterdam The Netherlands.
2
2 Prinses Máxima Center for Pediatric Oncology Utrecht The Netherlands.
3
3 Department of Cardiology Amsterdam UMC University of Amsterdam The Netherlands.
4
4 Department of Clinical Epidemiology, Biostatistics and Bioinformatics Academic Medical Center Amsterdam the Netherlands.
5
5 Oxford University Clinical Research Unit Wellcome Trust Major Overseas Programme Ho Chi Minh City Vietnam.
6
6 Nuffield Department of Medicine University of Oxford United Kingdom.
7
7 Department of Pediatric Oncology/Hematology VU University Medical Center Amsterdam The Netherlands.
8
8 Dutch Childhood Oncology Group-Late Effects after Childhood Cancer (DCOG-LATER) registry The Hague The Netherlands.
9
9 Department of Pediatric Oncology Erasmus MC/Sophia Children's Hospital Rotterdam The Netherlands.
10
10 Department of Epidemiology Netherlands Cancer Institute Amsterdam The Netherlands.
11
11 Department of Hematology Radboud University Nijmegen Medical Center Nijmegen The Netherlands.
12
12 Department of Pediatric Oncology University Medical Center Utrecht The Netherlands.
13
13 Department of Pediatric Oncology University of Groningen University Medical Center Groningen The Netherlands.

Abstract

Background Heart failure is one of the most important late effects after treatment for cancer in childhood. The goals of this study were to evaluate the risk of heart failure, temporal changes by treatment periods, and the risk factors for heart failure in childhood cancer survivors ( CCS ). Methods and Results The DCOG-LATER (Dutch Childhood Oncology Group-Long-Term Effects After Childhood Cancer) cohort includes 6,165 5-year CCS diagnosed between 1963 and 2002. Details on prior cancer diagnosis and treatment were collected for this nationwide cohort. Cause-specific cumulative incidences and risk factors of heart failure were obtained. Cardiac follow-up was complete for 5,845 CCS (94.8%). After a median follow-up of 19.8 years and at a median attained age of 27.3 years, 116 survivors developed symptomatic heart failure. The cumulative incidence of developing heart failure 40 years after childhood cancer diagnosis was 4.4% (3.4%-5.5%) among all CCS. The cumulative incidence of heart failure grade ≥3 among survivors treated in the more recent treatment periods was higher compared with survivors treated earlier (Gray test, P=0.05). Mortality due to heart failure decreased in the more recent treatment periods (Gray test, P=0.02). In multivariable analysis, survivors treated with a higher dose of mitoxantrone or cyclophosphamide had a higher risk of heart failure than survivors who were exposed to lower doses. Conclusions CCS treated with mitoxantrone, cyclophosphamide, anthracyclines, or radiotherapy involving the heart are at a high risk for severe, life-threatening or fatal heart failure at a young age. Although mortality decreased, the incidence of severe or life-threatening heart failure increased with more recent treatment periods.

KEYWORDS:

childhood cancer survivors; heart failure

PMID:
30595059
DOI:
10.1161/JAHA.118.009122
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center